Oxford Global’s 16th Annual Drug Discovery Leaders Summit and our co-located 3rd Annual Discovery 91AV and Drug Design Congress are Europe’s leading summits in the drug discovery and discovery chemistry field. Our prestigious summit brings together prominent decision makers working at the forefront of research into target based discovery, phenotypic screening, preclinical biomarkers, and medicinal chemistry.
Our summit will consist of 6 interactive streams covering:
- Target Based Discovery
- Screening and Assays: Enabling Technologies
- Preclinical Biomarkers and Translational Medicine
- Supporting Innovation: Data and Information Management
- Discovery 91AV: Latest Case Studies
- Drug Design: Novel Approaches
On day one our panel of discovery experts will explore the resurgence of phenotypic screening, the latest innovations in high content analysis and the search for physiologically relevant screen models, including 3D cell culture and stem cells. Day one also features a stream dedicated to the latest research in medicinal chemistry.
On day two delegates will hear from our industry leaders about the most promising new technologies for biomarkers and translational medicine, our data and information management stream will host exciting discussions about how to exploit Big Data for more efficient drug discovery and our third stream is dedicated to the most innovative approaches to drug design.
Our summit will consist of 6 interactive streams covering:
- Target Based Discovery
- Screening and Assays: Enabling Technologies
- Preclinical Biomarkers and Translational Medicine
- Supporting Innovation: Data and Information Management
- Discovery 91AV: Latest Case Studies
- Drug Design: Novel Approaches
On day one our panel of discovery experts will explore the resurgence of phenotypic screening, the latest innovations in high content analysis and the search for physiologically relevant screen models, including 3D cell culture and stem cells. Day one also features a stream dedicated to the latest research in medicinal chemistry.
On day two delegates will hear from our industry leaders about the most promising new technologies for biomarkers and translational medicine, our data and information management stream will host exciting discussions about how to exploit Big Data for more efficient drug discovery and our third stream is dedicated to the most innovative approaches to drug design.
